{"gene":"GRIN2B","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2010,"finding":"DAPK1 directly binds the NMDA receptor GluN2B C-terminal tail (amino acids 1292–1304) and, when constitutively active, phosphorylates GluN2B at Ser-1303, enhancing NR1/NR2B receptor channel conductance. Cerebral ischemia recruits DAPK1 into the GluN2B complex at extrasynaptic sites; genetic deletion of DAPK1 or a competing peptide (NR2B-CT) blocks injurious Ca2+ influx and is neuroprotective in mice.","method":"Co-immunoprecipitation, in vitro kinase assay, peptide competition, DAPK1 knockout mice, electrophysiology, stroke model","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay with phospho-site identification, reciprocal Co-IP, genetic KO, and peptide rescue in vivo; multiple orthogonal methods in a single rigorous study","pmids":["20141836"],"is_preprint":false},{"year":2007,"finding":"Dopamine D2 receptors (D2R) directly interact with the GluN2B subunit within the postsynaptic density of striatal neurons. Cocaine enhances this D2R–GluN2B complex formation, which disrupts CaMKII association with GluN2B, reduces GluN2B phosphorylation at Ser-1303, and inhibits NMDA receptor-mediated currents in striatal neurons.","method":"Co-immunoprecipitation, GST pulldown, electrophysiology, behavioral cocaine model","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus in vitro pulldown plus electrophysiology; multiple orthogonal methods","pmids":["17145509"],"is_preprint":false},{"year":2013,"finding":"Activated CaMKII couples GluN2B and casein kinase 2 (CK2) into a trimolecular complex, increasing CK2-mediated phosphorylation of GluN2B at S1480. A GluN2B mutant unable to bind CaMKII shows reduced S1480 phosphorylation and increased surface expression. Disrupting GluN2B/CaMKII binding reduces synapse number but increases synaptic GluN2B content.","method":"Co-immunoprecipitation, phospho-site mutagenesis, surface biotinylation, confocal imaging","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, mutagenesis, and surface expression assays with multiple orthogonal methods in one study","pmids":["23478024"],"is_preprint":false},{"year":2007,"finding":"CaMKII binding to the GluN2B C-terminal tail is required for CaMKII synaptic accumulation, Thr286 autophosphorylation, GluR1 phosphorylation, hippocampal LTP, and spatial learning. Transgenic expression of a C-terminal GluN2B fragment that sequesters endogenous CaMKII disrupts these interactions and impairs plasticity and memory.","method":"Transgenic mouse (ligand-inducible NR2B fragment), immunoprecipitation, electrophysiology (LTP), Morris water maze","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic disruption with defined molecular readouts (phosphorylation, LTP, behavior), multiple orthogonal assays","pmids":["18077696"],"is_preprint":false},{"year":2012,"finding":"Direct interaction between GluN2B and αCaMKII (but not βCaMKII) is required for GluN2B-dependent, long-lasting ERK1/2 phosphorylation following synaptic NMDAR activation. Disrupting this interaction prevents activity-induced increases in synaptic AMPA receptors and spine volume.","method":"Co-immunoprecipitation, pharmacological disruption of GluN2B/CaMKII binding, ERK phosphorylation assay, dendritic spine imaging","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, interaction-disrupting peptide, and multiple functional readouts in cultured cortical neurons","pmids":["22855824"],"is_preprint":false},{"year":2017,"finding":"DAPK1 competes with CaMKII for binding to GluN2B. During LTD, calcineurin-dependent DAPK1 activation blocks CaMKII binding to GluN2B, preventing CaMKII synaptic accumulation. During LTP, Ca2+/CaM inhibits DAPK1/GluN2B binding, allowing CaMKII accumulation. A pharmacogenetic approach confirmed that suppression of CaMKII/GluN2B binding is a DAPK1-specific function required for LTD.","method":"Pharmacogenetic approach (GluN2B knock-in mice), electrophysiology (LTP/LTD), biochemical competition assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacogenetic mouse model combined with electrophysiology and biochemical assays; multiple orthogonal methods","pmids":["28614711"],"is_preprint":false},{"year":2019,"finding":"GluN2B S1480 phosphorylation maintains NMDARs at extrasynaptic membranes within a complex containing protein phosphatase 1 (PP1). Global NMDAR activation leads to PP1 activation, which dephosphorylates GluN2B S1480 and promotes increased synaptic NMDAR content.","method":"Co-immunoprecipitation, phospho-site mutagenesis, surface biotinylation, electrophysiology","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, phospho-mutant analysis, and electrophysiology; multiple orthogonal methods in a single study","pmids":["31291571"],"is_preprint":false},{"year":2016,"finding":"CaMKII/GluN2B interaction is required not only for LTP induction but also for the maintenance of basal synaptic strength, as shown by pharmacogenetic disruption using a CaMKII-binding-incompetent GluN2B knock-in mouse.","method":"Pharmacogenetic mouse (GluN2B CaMKII-binding mutant knock-in), electrophysiology, CaMKII inhibitor tatCN21","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacogenetic knock-in mouse with clean electrophysiological readouts; separates on-target from off-target effects","pmids":["27246855"],"is_preprint":false},{"year":2024,"finding":"GluN2B binding to CaMKII directly generates Ca2+-independent autonomous CaMKII activity. This enzymatic activity is dispensable for LTP induction (within 5 min) but required for an intermediary LTP expression phase (within 15 min), providing an objective temporal definition for this LTP phase.","method":"Pharmacogenetic approach, electrophysiology, optogenetic CaMKII activation (CRY2 constructs), biochemical assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacogenetic plus optogenetic tools combined with electrophysiology; multiple orthogonal approaches in one study","pmids":["39395168"],"is_preprint":false},{"year":2014,"finding":"GluN1/GluN2A/GluN2B triheteromeric NMDA receptors have distinct glutamate deactivation kinetics compared with GluN1/GluN2A and GluN1/GluN2B diheteromers, and show unique modulation by ifenprodil, CP-101,606, TCN-201, and extracellular Zn2+. The ifenprodil binding site of triheteromers differs kinetically from that of GluN1/GluN2B diheteromers.","method":"Engineered forced-expression system for exclusive triheteromeric surface expression, whole-cell electrophysiology, pharmacological profiling","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1 / Strong — recombinant receptor reconstitution with selective surface expression system plus rigorous electrophysiology and pharmacology","pmids":["24607230"],"is_preprint":false},{"year":2021,"finding":"GluN2A and GluN2B receptors utilize distinct long-distance allosteric mechanisms involving different subunit–subunit interfaces and molecular rearrangements between their N-terminal domains (NTDs) and transmembrane channel pore.","method":"Functional electrophysiology combined with structural analysis (cryo-EM/X-ray), mutagenesis of subunit interfaces","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural interrogation combined with functional mutagenesis, multiple orthogonal methods","pmids":["34354080"],"is_preprint":false},{"year":2017,"finding":"DAPK1 interaction with GluN2B at extrasynaptic sites is enhanced by chronic stress (CUS) in the rat prefrontal cortex, increasing GluN2B-mediated NMDA currents and extrasynaptic responses. Uncoupling DAPK1 from GluN2B (via DAPK1 knockdown, pharmacological inhibition, or competing peptide) produces rapid antidepressant-like effects and reverses CUS-induced synaptic deficits.","method":"AAV-shRNA knockdown, pharmacological inhibition, competing peptide, electrophysiology, behavioral tests","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple intervention strategies (genetic KD, pharmacology, peptide) with convergent electrophysiological and behavioral readouts","pmids":["28439098"],"is_preprint":false},{"year":2010,"finding":"Tyrosine phosphorylation of GluN2B at Tyr-1472 (the major phosphorylation site) negatively regulates anxiety-like behavior and CRF expression in the amygdala. Knock-in mice expressing GluN2B Y1472F (phosphorylation-deficient) show enhanced anxiety and elevated amygdalar CRF expression; CRF receptor antagonism attenuates this enhanced anxiety.","method":"Knock-in mice (Y1472F GluN2B), elevated plus-maze, CRF immunoassay, CRF receptor antagonist injection","journal":"Molecular brain","confidence":"High","confidence_rationale":"Tier 2 / Strong — phospho-site knock-in mouse with pharmacological rescue and multiple behavioral and molecular readouts","pmids":["21118530"],"is_preprint":false},{"year":2010,"finding":"Src tyrosine kinase regulates GluN2B surface expression in amygdala neurons. A cell-permeable Src inhibitory peptide (Tat-Src 40-58) reduces GluN2B tyrosine phosphorylation and surface expression in amygdala neurons, blocks amygdalar LTP, and impairs amygdala-dependent fear conditioning and social recognition memory.","method":"Cell-permeable peptide, surface biotinylation, electrophysiology (LTP), fear conditioning behavioral assay","journal":"Learning & memory","confidence":"High","confidence_rationale":"Tier 2 / Strong — peptide intervention with biochemical (phosphorylation, surface expression), electrophysiological, and behavioral readouts","pmids":["20660101"],"is_preprint":false},{"year":2015,"finding":"GluN2B-containing NMDARs anchor the synaptic proteasome, regulating constitutive AMPA receptor endocytosis. In GluN2B-knockout neurons, synaptic proteasome subunit levels decrease, GluA1-AMPA receptor constitutive endocytosis is reduced, and synaptic AMPA receptor levels increase. Pharmacological enhancement of proteasome activity rescues these phenotypes.","method":"GluN2B-/- neuronal cultures, quantitative postsynaptic density proteomics, surface biotinylation, proteasome activator treatment","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO combined with quantitative proteomics and pharmacological rescue; multiple orthogonal readouts","pmids":["26041915"],"is_preprint":false},{"year":2018,"finding":"Noonan syndrome-associated SHP2 dephosphorylates GluN2B at Y1252 (identified as an SHP2 substrate in vitro and in vivo). Phospho-Y1252 binds the actin-regulatory adaptor protein Nck2, and this interaction is required for proper NMDAR function. NS mice show selectively reduced GluN1:GluN2B diheteromer contribution to NMDAR currents.","method":"In vitro phosphatase assay, mass spectrometry, Co-immunoprecipitation, electrophysiology, NS knock-in mice","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro phosphatase assay with site identification, Co-IP, and electrophysiology in knock-in mice; multiple orthogonal methods","pmids":["30089263"],"is_preprint":false},{"year":2015,"finding":"PKC activation in the arcuate nucleus enhances phosphorylation of GluN2B at Tyr-1472 without altering total GluN2B expression. Intra-ARC injection of the PKC inhibitor chelerythrine reverses CFA-induced upregulation of phospho-GluN2B(Tyr1472) and attenuates inflammatory hyperalgesia.","method":"In vivo microinjection, western blotting, in vivo extracellular electrophysiology, inflammatory pain model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological intervention with phospho-site western blotting and electrophysiology; single lab, two methods","pmids":["26515544"],"is_preprint":false},{"year":2017,"finding":"D-serine (but not glycine) alters the membrane dynamics and synaptic content of GluN2B-NMDARs (but not GluN2A-NMDARs) through a process requiring PDZ-binding scaffold partners. D-serine also rapidly induces a conformational change of the GluN1 subunit intracellular C-terminus domain, detected by FRET-FLIM.","method":"Single-molecule tracking, surface biotinylation, FRET-FLIM, electrophysiology, ex vivo and in vitro pharmacology","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — single-molecule imaging, FRET-FLIM, and electrophysiology provide multiple orthogonal lines of evidence in one study","pmids":["28598327"],"is_preprint":false},{"year":2019,"finding":"An ASD-associated truncating mutation in GluN2B (within the extracellular loop) abolishes NMDA-dependent Ca2+ influx. Mutant GluN2B co-assembles with GluN1 but is not trafficked to the cell surface or dendrites, and when expressed in developing cortical neurons causes shorter, fewer dendritic branches and dysmorphic filopodial-like structures even on a wild-type background.","method":"Calcium imaging, surface biotinylation, immunocytochemistry, dendritic morphology analysis in primary cortical neurons, HEK293 expression","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional Ca2+ assay, trafficking assay, and morphological analysis with multiple GluN2B constructs in primary neurons","pmids":["31548203"],"is_preprint":false},{"year":2019,"finding":"TMEM25 interacts with GluN2B and co-localizes with it in late endosomes. TMEM25 induces lysosomal acidification and accelerates GluN2B degradation. Loss of TMEM25 increases GluN2B levels and neuronal excitability, while TMEM25 overexpression attenuates epileptic seizure phenotypes.","method":"Co-immunoprecipitation, confocal co-localization, lysosomal acidification assay, electrophysiology, overexpression/knockdown in mice, epilepsy model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP, co-localization, degradation assay, electrophysiology, and in vivo gain/loss-of-function; multiple orthogonal methods","pmids":["31424425"],"is_preprint":false},{"year":2020,"finding":"Leptin receptor (LepRb) forms a complex with GluN2B and Fyn kinase. Leptin stimulates Fyn-dependent phosphorylation of GluN2B at Tyr-1472, increasing surface expression of NR2B-containing NMDARs. Blocking Y1472 phosphorylation (via dominant-negative Fyn or NR2B-Y1472F mutant) prevents leptin-stimulated glutamatergic synaptogenesis in hippocampal neurons.","method":"Co-immunoprecipitation, surface biotinylation, phospho-site mutagenesis, synapse morphometry, dominant-negative Fyn","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP, mutagenesis, surface trafficking assay, and synaptogenesis readout; multiple orthogonal methods in one study","pmids":["31840160"],"is_preprint":false},{"year":2014,"finding":"Nicotinic and muscarinic ACh receptor agonists and acetylcholinesterase inhibitors converge on the m1 muscarinic receptor–Gαq–PKC–PYK2–Src signaling pathway to selectively enhance GluN2B-NMDAR responses in hippocampal CA1 pyramidal cells. In vivo cholinergic drug exposure occludes in vitro m1 and Src potentiation of NMDAR responses.","method":"In vivo drug administration, in vitro electrophysiology (whole-cell patch clamp), pharmacological dissection","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo–in vitro occlusion paradigm with multiple pharmacological probes defining a signaling pathway","pmids":["25114227"],"is_preprint":false},{"year":2010,"finding":"PKA phosphorylation of CASK at Thr-724 in the guanylate kinase domain upregulates the CASK–Tbr-1 interaction. This complex activates the NMDAR2B promoter, and T724A CASK mutation abolishes cAMP-stimulated NMDAR2B expression in cortical neurons.","method":"In vitro PKA kinase assay, site-directed mutagenesis, Co-immunoprecipitation, NMDAR2B promoter-reporter assay, cortical neuron culture","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay with phospho-site identification, mutagenesis, Co-IP, and promoter reporter assay; multiple orthogonal methods","pmids":["20067577"],"is_preprint":false},{"year":2009,"finding":"CASK Thr-724 point mutation in the GK domain selectively reduces CASK interactions with Tbr-1 and CINAP without affecting CASK dimerization, and diminishes NMDAR2B (NR2b) promoter activity, confirming that the CASK–Tbr-1–CINAP complex is required for NMDAR2B transcriptional regulation.","method":"Site-directed mutagenesis, Co-immunoprecipitation, promoter-reporter assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus Co-IP plus promoter assay, single lab; confirms and extends PMID 20067577","pmids":["19275891"],"is_preprint":false},{"year":2008,"finding":"Activity suppression (TTX treatment) increases GluN2B mRNA expression in cortical neurons, and this upregulation is occluded by DNMT inhibition. MeCP2 binds to the NR2B gene, and TTX reduces MeCP2 association with the NR2B locus, indicating that DNA methylation and MeCP2 binding mediate activity-dependent regulation of NR2B expression.","method":"TTX treatment of cortical neurons, RT-qPCR, chromatin immunoprecipitation (ChIP), DNMT inhibitor treatment, dark-rearing model","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP combined with pharmacological and activity-deprivation experiments; single lab, two orthogonal methods","pmids":["18952054"],"is_preprint":false},{"year":2015,"finding":"GluN2B(F637) in the third membrane-associated domain regulates ethanol sensitivity and ion channel gating. Substitution mutations at F637 significantly alter ethanol IC50 values and glutamate EC50 values for peak and steady-state current, demonstrating this residue as a functional determinant of alcohol action on GluN2B-containing NMDARs.","method":"Site-directed mutagenesis, two-electrode voltage clamp in Xenopus oocytes, ethanol concentration–response analysis","journal":"Neuropharmacology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with functional electrophysiology; systematic structure–function analysis of ion channel residue","pmids":["26051400"],"is_preprint":false},{"year":2022,"finding":"HECTD4 (an E3 ubiquitin ligase) interacts with GluN2B and ubiquitinates it. Ischemic stroke weakens this HECTD4–GluN2B interaction and reduces GluN2B ubiquitination. HECTD4 knockdown exacerbates NMDA/hypoxia-induced injury with increased GluN2B phosphorylation and Ca2+ overload, while MALT1 acts downstream of HECTD4 to regulate STEP61 and GluN2B phosphorylation.","method":"Nano-LC-MS/MS (interactome), Co-immunoprecipitation, siRNA knockdown, ubiquitination assay, Ca2+ imaging, ischemia rat model","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, and Ca2+ imaging; single lab with several orthogonal methods","pmids":["36527595"],"is_preprint":false},{"year":2020,"finding":"Synaptotagmin-7 (Syt7) and GluN2B-NMDARs co-localize at the peripheral synaptic region in hippocampal neurons. Syt7 triggers multiple forms of glutamate release to activate juxtaposed GluN2B-NMDARs. Syt7 deficiency causes GluN2B-NMDAR hypoactivity and mania-like behavior in mice; this hypoactivity was rescued by Syt7 overexpression in patient iPSC-derived neurons.","method":"Super-resolution imaging, iPSC-derived neuron electrophysiology, Syt7 KO mice, lentiviral overexpression, behavioral assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — super-resolution co-localization, genetic KO, iPSC rescue experiment, and electrophysiology; multiple orthogonal methods","pmids":["33229564"],"is_preprint":false},{"year":2022,"finding":"CK2 is aberrantly elevated in Alzheimer's disease (AD) brains, causing GluN2B to mislocalize from synaptic to extrasynaptic sites. CK2 inhibition corrects this NR2B synaptic distribution, reduces tau accumulation in vitro, and inhibiting excessive extrasynaptic GluN2B with memantine also mitigates tau pathology.","method":"Human AD brain immunohistochemistry, hippocampal neuron culture (AD-tau treatment), CK2 inhibitor treatment, synaptic fractionation, tau immunoassay","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human tissue combined with in vitro pharmacological rescue; single lab, two orthogonal approaches","pmids":["35246269"],"is_preprint":false},{"year":2017,"finding":"Conditional deletion of the GluN2B C-terminal tail (amino acids 886–1269) in forebrain excitatory neurons disrupts DAPK1–GluN2B interaction and inhibits extrasynaptic but not synaptic NMDAR currents. This genetic manipulation protects neurons against ischemic stroke damage and improves behavioral outcomes in vivo.","method":"Conditional knockout mice, whole-cell electrophysiology, infarct volume measurement, behavioral tests","journal":"Molecular neurobiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with site-specific electrophysiological dissection of synaptic vs extrasynaptic currents, plus in vivo stroke model","pmids":["28456939"],"is_preprint":false},{"year":2021,"finding":"GluN2B-containing NMDARs are required for extinction memory destabilization upon recall (shown by GluN2B antagonist RO25-6981 blocking reconsolidation-mediated memory recovery), whereas GluN2A-containing NMDARs are involved in restabilization (shown by GluN2A antagonist TCN201 impairment of retention).","method":"Intra-hippocampal drug microinfusion, inhibitory avoidance behavioral paradigm, pharmacological dissection","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological dissection with selective antagonists; single lab, behavioral readout","pmids":["33420399"],"is_preprint":false},{"year":2016,"finding":"Amphetamine and methamphetamine increase GluN2B-NMDAR synaptic currents in midbrain dopamine neurons dependent on dopamine transporter-mediated drug entry. EAAT3 internalization caused by AMPH increases extracellular glutamate to activate GluN2B-containing NMDARs. GluN2B inhibitors reduce MA-stimulated locomotor activity without affecting basal activity.","method":"Whole-cell patch clamp in midbrain slices, selective GluN2B antagonists, MK-801 use-dependent block, dopamine transporter inhibition, behavioral locomotor assay","journal":"Neuropsychopharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — electrophysiology with multiple pharmacological probes plus use-dependent blocker to distinguish surface vs de novo receptor pools; behavioral confirmation","pmids":["27976681"],"is_preprint":false},{"year":2014,"finding":"GluN2B and GluN2D play counteractive roles in the temporal development of somatosensory maps: GluN2B is expressed at asymmetric synapses of glutamatergic projection neurons and facilitates refinement of ascending pathway synapses, while GluN2D is expressed at asymmetric synapses of GABAergic interneurons and delays it indirectly.","method":"GluN2B+/- and GluN2D-/- mice, unilateral infraorbital nerve transection (critical period assay), immunoelectron microscopy for subunit localization","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic mouse models with anatomical subunit localization by immuno-EM and functional critical-period assays; multiple orthogonal methods","pmids":["25164652"],"is_preprint":false},{"year":2007,"finding":"PSD-95 is required for dopamine D1 receptor modulation of GluN1a/GluN2B receptor function. D1R stimulation increases NMDA-mediated Ca2+ influx only when PSD-95 is co-expressed; this modulation is blocked by PKA and PKC inhibitors.","method":"HEK293 cell co-expression, Ca2+ imaging, pharmacological inhibition of PKA and PKC","journal":"Acta pharmacologica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional Ca2+ assay with pharmacological dissection; single lab, recombinant system","pmids":["17506933"],"is_preprint":false},{"year":1994,"finding":"The human GRIN2B gene, encoding the NMDAR2B receptor subunit, was mapped to chromosome 12p12 by in situ hybridization and somatic cell hybrid analysis.","method":"Fluorescence in situ hybridization, somatic cell hybrid panel","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent mapping methods (FISH + somatic cell hybrids); foundational chromosomal localization","pmids":["7959773"],"is_preprint":false}],"current_model":"GluN2B is the glutamate-binding regulatory subunit of diheteromeric (GluN1/GluN2B) and triheteromeric (GluN1/GluN2A/GluN2B) NMDA receptors that functions as a scaffold and signaling hub at postsynaptic densities and extrasynaptic membranes: its C-terminal tail directly binds CaMKII (promoting autonomous kinase activity and LTP), DAPK1 (which phosphorylates Ser-1303 to enhance channel conductance and mediate excitotoxic/LTD signaling), CK2 (which phosphorylates S1480 to control synaptic vs. extrasynaptic trafficking), Src/Fyn kinases (which phosphorylate Tyr-1472 to regulate surface expression and anxiety-related behavior), PP1 (which dephosphorylates S1480 to promote synaptic recruitment), and the E3 ligase HECTD4 (which ubiquitinates GluN2B to control its degradation), while the transmembrane domain residue F637 determines ethanol sensitivity; transcription of GRIN2B is regulated by the CASK–Tbr-1 complex (PKA-dependent), MeCP2-mediated DNA methylation, and epigenetic modifications including promoter hypermethylation."},"narrative":{"mechanistic_narrative":"GRIN2B encodes GluN2B, the glutamate-binding regulatory subunit of NMDA-type glutamate receptors that assemble as GluN1/GluN2B diheteromers and GluN1/GluN2A/GluN2B triheteromers, the latter exhibiting distinct deactivation kinetics and pharmacology (ifenprodil, Zn2+) from either diheteromer [PMID:24607230], with GluN2A and GluN2B receptors using divergent long-distance allosteric coupling between N-terminal domains and the channel pore [PMID:34354080]. The GluN2B C-terminal tail is a signaling and trafficking hub: it directly binds αCaMKII, an interaction that drives CaMKII synaptic accumulation, Thr286 autophosphorylation, GluR1 phosphorylation, ERK1/2 signaling, spine growth, hippocampal LTP, basal synaptic strength, and spatial learning, and additionally generates Ca2+-independent autonomous CaMKII activity required for an intermediary LTP phase [PMID:18077696, PMID:22855824, PMID:27246855, PMID:39395168]. DAPK1 competes with CaMKII for the same C-terminal region; calcineurin-dependent DAPK1 activation displaces CaMKII during LTD, while DAPK1 recruited to extrasynaptic GluN2B phosphorylates Ser-1303 to enhance channel conductance and drive excitotoxic Ca2+ influx in ischemia, chronic stress, and depression-related signaling [PMID:20141836, PMID:28614711, PMID:28439098, PMID:28456939]. Phosphorylation toggles control receptor localization: CaMKII couples GluN2B to CK2 to phosphorylate S1480 and retain receptors extrasynaptically, PP1 dephosphorylates S1480 to promote synaptic recruitment, and Src/Fyn-mediated Tyr-1472 phosphorylation (downstream of m1-Gαq-PKC-PYK2 and leptin receptor signaling) controls surface expression, anxiety behavior, fear memory, and synaptogenesis [PMID:23478024, PMID:31291571, PMID:20660101, PMID:31840160, PMID:25114227], while SHP2 dephosphorylates Tyr-1252 to govern Nck2 binding and receptor function [PMID:30089263]. GluN2B levels are further set by degradation via the E3 ligase HECTD4 and TMEM25-driven lysosomal turnover, and by anchoring of the synaptic proteasome that controls AMPA receptor endocytosis [PMID:26041915, PMID:31424425, PMID:36527595]. GRIN2B transcription is regulated by the PKA-dependent CASK–Tbr-1–CINAP complex and by activity-dependent DNA methylation/MeCP2 binding [PMID:20067577, PMID:19275891, PMID:18952054]. GluN2B-containing receptors mediate distinct cellular roles including somatosensory map refinement, extinction-memory destabilization, and responses to drugs of abuse, and a truncating ASD-associated mutation abolishes surface trafficking and Ca2+ influx and disrupts dendritic morphology [PMID:31548203, PMID:33420399, PMID:27976681, PMID:25164652].","teleology":[{"year":1994,"claim":"Establishing the chromosomal location of the human gene encoding the NMDAR2B subunit provided the genomic foundation for studying GRIN2B in human disease.","evidence":"FISH and somatic cell hybrid mapping to 12p12","pmids":["7959773"],"confidence":"High","gaps":["No functional or regulatory information","Does not address protein function or interactions"]},{"year":2007,"claim":"Defining the requirement of direct CaMKII binding to the GluN2B C-terminal tail answered how NMDAR activation is transduced into synaptic plasticity and memory.","evidence":"Transgenic CaMKII-sequestering GluN2B fragment with LTP and Morris water maze readouts; co-expression Ca2+ imaging with PSD-95","pmids":["18077696","17506933"],"confidence":"High","gaps":["Did not resolve the temporal phases of CaMKII-dependent LTP","Competition with other C-tail binders not yet addressed"]},{"year":2010,"claim":"Identifying DAPK1 as a direct GluN2B partner that phosphorylates Ser-1303 at extrasynaptic sites revealed the molecular route from receptor to excitotoxic Ca2+ influx in stroke.","evidence":"Co-IP, in vitro kinase assay, DAPK1 KO mice, competing peptide in a stroke model","pmids":["20141836"],"confidence":"High","gaps":["Did not yet establish DAPK1/CaMKII mutual exclusivity","Synaptic vs extrasynaptic substrate selectivity mechanism unresolved"]},{"year":2010,"claim":"Linking Src/Fyn-dependent Tyr-1472 phosphorylation to GluN2B surface expression connected tyrosine signaling to anxiety and fear-related behaviors.","evidence":"Y1472F knock-in mice, Tat-Src inhibitory peptide, surface biotinylation, LTP and behavioral assays in amygdala","pmids":["21118530","20660101"],"confidence":"High","gaps":["Upstream kinase activation signals not fully mapped","Phosphatase counteracting Y1472 not identified here"]},{"year":2013,"claim":"Showing that activated CaMKII recruits CK2 to phosphorylate S1480 explained how a plasticity signal controls synaptic versus extrasynaptic receptor distribution.","evidence":"Co-IP, phospho-site mutagenesis, surface biotinylation, imaging","pmids":["23478024"],"confidence":"High","gaps":["Phosphatase reversing S1480 not yet identified","In vivo relevance of the trimolecular complex untested"]},{"year":2014,"claim":"Engineered triheteromeric receptors and subunit-localization studies resolved that GluN2B confers distinct kinetics, pharmacology, and developmental/circuit roles separable from GluN2A and GluN2D.","evidence":"Forced triheteromer surface expression with electrophysiology/pharmacology; GluN2B+/- and GluN2D-/- mice with immuno-EM and critical-period assays; cholinergic m1-PKC-PYK2-Src pathway dissection","pmids":["24607230","25164652","25114227"],"confidence":"High","gaps":["Native triheteromer stoichiometry in vivo not quantified","Structural basis of altered ifenprodil site not yet resolved"]},{"year":2015,"claim":"Mapping a transmembrane determinant (F637) of ethanol and gating, plus a proteasome-anchoring role, expanded GluN2B function beyond ligand binding into channel pharmacology and protein turnover at synapses.","evidence":"F637 mutagenesis with two-electrode voltage clamp; GluN2B-/- neurons with PSD proteomics and proteasome activator rescue; PKC-Tyr1472 pain model","pmids":["26051400","26041915","26515544"],"confidence":"High","gaps":["F637 ethanol mechanism is structure-function only, no in vivo behavior","How GluN2B physically anchors the proteasome unresolved"]},{"year":2017,"claim":"Demonstrating DAPK1/CaMKII mutual competition for GluN2B unified bidirectional plasticity, showing the same C-tail site switches between LTP and LTD depending on calcium signaling.","evidence":"Pharmacogenetic GluN2B knock-in mice, LTP/LTD electrophysiology, biochemical competition; D-serine single-molecule and FRET-FLIM trafficking study","pmids":["28614711","27246855","28598327"],"confidence":"High","gaps":["Timing of calcineurin-DAPK1 versus Ca2+/CaM signals not fully resolved","Coactivator selectivity (D-serine vs glycine) mechanism partial"]},{"year":2019,"claim":"Identifying PP1-mediated S1480 dephosphorylation and TMEM25/lysosomal degradation defined the bidirectional control of GluN2B synaptic recruitment and abundance, while an ASD truncation linked trafficking failure to morphological disease phenotypes.","evidence":"Co-IP/phospho-mutant electrophysiology (PP1); Co-IP, lysosomal acidification and epilepsy model (TMEM25); Ca2+ imaging and dendritic morphology of ASD truncation","pmids":["31291571","31424425","31548203"],"confidence":"High","gaps":["How global NMDAR activity selectively activates PP1 at S1480 unknown","Disease-mutation dominant-negative mechanism on WT receptors not fully defined"]},{"year":2020,"claim":"Connecting leptin receptor–Fyn–Tyr1472 signaling and Syt7-driven peripheral glutamate release placed GluN2B activity within metabolic and presynaptic release contexts relevant to synaptogenesis and mood.","evidence":"Co-IP, dominant-negative Fyn, synaptogenesis (leptin); super-resolution imaging, Syt7 KO mice and iPSC rescue (Syt7)","pmids":["31840160","33229564"],"confidence":"High","gaps":["Spatial organization of the LepRb-GluN2B-Fyn complex unresolved","Direct vs indirect Syt7-GluN2B coupling not biochemically defined"]},{"year":2022,"claim":"Establishing HECTD4-mediated ubiquitination and CK2-driven extrasynaptic mislocalization tied GluN2B degradation and distribution to ischemic injury and Alzheimer's tau pathology.","evidence":"Interactome MS, Co-IP, ubiquitination and Ca2+ imaging in ischemia (HECTD4); human AD brain plus CK2 inhibitor and memantine rescue (CK2)","pmids":["36527595","35246269"],"confidence":"Medium","gaps":["HECTD4 ubiquitination sites on GluN2B not mapped","Causality between CK2-driven mislocalization and tau accumulation is correlative in human tissue"]},{"year":2024,"claim":"Resolving that GluN2B-induced autonomous CaMKII activity is dispensable for LTP induction but required for an intermediary expression phase gave a temporal mechanistic definition to CaMKII-dependent plasticity.","evidence":"Pharmacogenetic and optogenetic (CRY2) CaMKII activation with electrophysiology and biochemistry","pmids":["39395168"],"confidence":"High","gaps":["Downstream effectors of the autonomous activity in the 15-min phase not identified","Relation to late-phase consolidation not addressed"]},{"year":null,"claim":"How the competing C-terminal interactions (CaMKII, DAPK1, CK2, PP1, Src/Fyn, SHP2, HECTD4) are spatially and temporally coordinated into a single integrated decision about GluN2B localization, conductance, and degradation remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of competitive C-tail occupancy in vivo","Stoichiometry of native synaptic vs extrasynaptic complexes unknown","Quantitative cross-regulation among phospho-sites not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[9,10,18]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,3,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,6,13,20]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[19]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[3,9,32]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,13,21]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[22,23,24]}],"complexes":["GluN1/GluN2B NMDA receptor","GluN1/GluN2A/GluN2B triheteromeric NMDA receptor","CASK-Tbr-1-CINAP transcription complex"],"partners":["CAMK2A","DAPK1","CSNK2A1","PPP1CA","FYN","PTPN11","HECTD4","TMEM25"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13224","full_name":"Glutamate receptor ionotropic, NMDA 2B","aliases":["Glutamate [NMDA] receptor subunit epsilon-2","N-methyl D-aspartate receptor subtype 2B","NMDAR2B","NR2B","N-methyl-D-aspartate receptor subunit 3","NR3","hNR3"],"length_aa":1484,"mass_kda":166.4,"function":"Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed:24272827, PubMed:24863970, PubMed:26875626, PubMed:26919761, PubMed:27839871, PubMed:28095420, PubMed:28126851, PubMed:38538865, PubMed:8768735). Participates in synaptic plasticity for learning and memory formation by contributing to the long-term depression (LTD) of hippocampus membrane currents (By similarity). Channel activation requires binding of the neurotransmitter L-glutamate to the GluN2 subunit, glycine or D-serine binding to the GluN1 subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) (PubMed:24272827, PubMed:24863970, PubMed:26875626, PubMed:26919761, PubMed:27839871, PubMed:28095420, PubMed:28126851, PubMed:38538865, PubMed:8768735). NMDARs mediate simultaneously the potassium efflux and the influx of calcium and sodium (By similarity). Each GluN2 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators (PubMed:26875626, PubMed:28095420, PubMed:28126851, PubMed:38538865, PubMed:8768735). In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death (By similarity)","subcellular_location":"Cell membrane; Postsynaptic cell membrane; Cell projection, dendrite; Late endosome; Lysosome; Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/Q13224/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GRIN2B","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GRIN2B","total_profiled":1310},"omim":[{"mim_id":"618306","title":"PROLINE-RICH PROTEIN 7; PRR7","url":"https://www.omim.org/entry/618306"},{"mim_id":"616250","title":"NACHT DOMAIN- AND WD REPEAT-CONTAINING PROTEIN 1; NWD1","url":"https://www.omim.org/entry/616250"},{"mim_id":"616139","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 27; DEE27","url":"https://www.omim.org/entry/616139"},{"mim_id":"615943","title":"MEMBRANE-ASSOCIATED GUANYLATE KINASE, WW AND PDZ DOMAINS-CONTAINING, 3; MAGI3","url":"https://www.omim.org/entry/615943"},{"mim_id":"614795","title":"1-@ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 4; AGPAT4","url":"https://www.omim.org/entry/614795"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Primary cilium tip","reliability":"Additional"},{"location":"Primary cilium transition zone","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"brain","ntpm":6.8}],"url":"https://www.proteinatlas.org/search/GRIN2B"},"hgnc":{"alias_symbol":["GluN2B","NR2B"],"prev_symbol":["NMDAR2B"]},"alphafold":{"accession":"Q13224","domains":[{"cath_id":"3.40.50.2300","chopping":"35-387","consensus_level":"medium","plddt":84.0481,"start":35,"end":387},{"cath_id":"3.40.190.10","chopping":"405-530_772-783","consensus_level":"medium","plddt":86.7572,"start":405,"end":783}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13224","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13224-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13224-F1-predicted_aligned_error_v6.png","plddt_mean":60.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GRIN2B","jax_strain_url":"https://www.jax.org/strain/search?query=GRIN2B"},"sequence":{"accession":"Q13224","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13224.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13224/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13224"}},"corpus_meta":[{"pmid":"20141836","id":"PMC_20141836","title":"DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20141836","citation_count":420,"is_preprint":false},{"pmid":"20890276","id":"PMC_20890276","title":"Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20890276","citation_count":404,"is_preprint":false},{"pmid":"24607230","id":"PMC_24607230","title":"Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors.","date":"2014","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/24607230","citation_count":260,"is_preprint":false},{"pmid":"28945221","id":"PMC_28945221","title":"α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B.","date":"2017","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28945221","citation_count":229,"is_preprint":false},{"pmid":"24298164","id":"PMC_24298164","title":"GluN2A and GluN2B subunit-containing NMDA receptors in hippocampal plasticity.","date":"2013","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24298164","citation_count":224,"is_preprint":false},{"pmid":"17145509","id":"PMC_17145509","title":"Modulation of D2R-NR2B interactions in response to cocaine.","date":"2006","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/17145509","citation_count":198,"is_preprint":false},{"pmid":"27818011","id":"PMC_27818011","title":"Human GRIN2B variants in neurodevelopmental disorders.","date":"2016","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27818011","citation_count":193,"is_preprint":false},{"pmid":"19789073","id":"PMC_19789073","title":"Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain.","date":"2009","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19789073","citation_count":155,"is_preprint":false},{"pmid":"16376149","id":"PMC_16376149","title":"Glutamate-based therapeutic approaches: NR2B receptor antagonists.","date":"2005","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16376149","citation_count":148,"is_preprint":false},{"pmid":"18077696","id":"PMC_18077696","title":"Interactions between the NR2B receptor and CaMKII modulate synaptic plasticity and spatial learning.","date":"2007","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18077696","citation_count":145,"is_preprint":false},{"pmid":"19192303","id":"PMC_19192303","title":"Plasticity of NMDA receptor NR2B subunit in memory and chronic pain.","date":"2009","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/19192303","citation_count":144,"is_preprint":false},{"pmid":"19562769","id":"PMC_19562769","title":"Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease.","date":"2009","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/19562769","citation_count":130,"is_preprint":false},{"pmid":"31807283","id":"PMC_31807283","title":"Distinct roles of GRIN2A and GRIN2B variants in neurological conditions.","date":"2019","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/31807283","citation_count":115,"is_preprint":false},{"pmid":"17010153","id":"PMC_17010153","title":"Association of the glutamate receptor subunit gene GRIN2B with attention-deficit/hyperactivity disorder.","date":"2006","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/17010153","citation_count":100,"is_preprint":false},{"pmid":"16549338","id":"PMC_16549338","title":"N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels.","date":"2006","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/16549338","citation_count":100,"is_preprint":false},{"pmid":"11945135","id":"PMC_11945135","title":"NR2B selective NMDA receptor antagonists.","date":"2002","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/11945135","citation_count":94,"is_preprint":false},{"pmid":"23478024","id":"PMC_23478024","title":"Activated CaMKII couples GluN2B and casein kinase 2 to control synaptic NMDA receptors.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23478024","citation_count":93,"is_preprint":false},{"pmid":"28439098","id":"PMC_28439098","title":"Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects.","date":"2017","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/28439098","citation_count":88,"is_preprint":false},{"pmid":"16141268","id":"PMC_16141268","title":"Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones.","date":"2005","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16141268","citation_count":88,"is_preprint":false},{"pmid":"19225220","id":"PMC_19225220","title":"Effects of chronic noise exposure on spatial learning and memory of rats in relation to neurotransmitters and NMDAR2B alteration in the hippocampus.","date":"2009","source":"Journal of occupational health","url":"https://pubmed.ncbi.nlm.nih.gov/19225220","citation_count":86,"is_preprint":false},{"pmid":"28598327","id":"PMC_28598327","title":"Co-agonists differentially tune GluN2B-NMDA receptor trafficking at hippocampal synapses.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28598327","citation_count":85,"is_preprint":false},{"pmid":"11317224","id":"PMC_11317224","title":"Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia.","date":"2001","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/11317224","citation_count":81,"is_preprint":false},{"pmid":"28614711","id":"PMC_28614711","title":"DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28614711","citation_count":74,"is_preprint":false},{"pmid":"24114429","id":"PMC_24114429","title":"A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression.","date":"2013","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24114429","citation_count":73,"is_preprint":false},{"pmid":"27246855","id":"PMC_27246855","title":"The CaMKII/GluN2B Protein Interaction Maintains Synaptic Strength.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27246855","citation_count":69,"is_preprint":false},{"pmid":"17224684","id":"PMC_17224684","title":"Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE review and meta-analysis.","date":"2007","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17224684","citation_count":60,"is_preprint":false},{"pmid":"22855824","id":"PMC_22855824","title":"Interaction between αCaMKII and GluN2B controls ERK-dependent plasticity.","date":"2012","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22855824","citation_count":59,"is_preprint":false},{"pmid":"23085545","id":"PMC_23085545","title":"Neuroprotective effect of estrogen: role of nonsynaptic NR2B-containing NMDA receptors.","date":"2012","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/23085545","citation_count":55,"is_preprint":false},{"pmid":"17620329","id":"PMC_17620329","title":"Quantitative hypermethylation of NMDAR2B in human gastric cancer.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17620329","citation_count":54,"is_preprint":false},{"pmid":"29682799","id":"PMC_29682799","title":"The differences between GluN2A and GluN2B signaling in the brain.","date":"2018","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/29682799","citation_count":51,"is_preprint":false},{"pmid":"29937144","id":"PMC_29937144","title":"Disruption of GRIN2B Impairs Differentiation in Human Neurons.","date":"2018","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29937144","citation_count":51,"is_preprint":false},{"pmid":"22850629","id":"PMC_22850629","title":"Glutamatergic GRIN2B and polyaminergic ODC1 genes in suicide attempts: associations and gene-environment interactions with childhood/adolescent physical assault.","date":"2012","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22850629","citation_count":48,"is_preprint":false},{"pmid":"25164652","id":"PMC_25164652","title":"Opposing role of NMDA receptor GluN2B and GluN2D in somatosensory development and maturation.","date":"2014","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25164652","citation_count":48,"is_preprint":false},{"pmid":"36704660","id":"PMC_36704660","title":"GRIN2B-related neurodevelopmental disorder: current understanding of pathophysiological mechanisms.","date":"2023","source":"Frontiers in synaptic neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36704660","citation_count":47,"is_preprint":false},{"pmid":"30054528","id":"PMC_30054528","title":"Prenatal Bisphenol A Exposure is Linked to Epigenetic Changes in Glutamate Receptor Subunit Gene Grin2b in Female Rats and Humans.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30054528","citation_count":44,"is_preprint":false},{"pmid":"22433450","id":"PMC_22433450","title":"Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder.","date":"2012","source":"Journal of psychiatry & neuroscience : JPN","url":"https://pubmed.ncbi.nlm.nih.gov/22433450","citation_count":42,"is_preprint":false},{"pmid":"31743763","id":"PMC_31743763","title":"Ginger extract and its compound, 6-shogaol, attenuates painful diabetic neuropathy in mice via reducing TRPV1 and NMDAR2B expressions in the spinal cord.","date":"2019","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31743763","citation_count":41,"is_preprint":false},{"pmid":"20660101","id":"PMC_20660101","title":"Src inhibition reduces NR2B surface expression and synaptic plasticity in the amygdala.","date":"2010","source":"Learning & memory (Cold Spring Harbor, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20660101","citation_count":41,"is_preprint":false},{"pmid":"24042122","id":"PMC_24042122","title":"Metabolism studies of ifenprodil, a potent GluN2B receptor antagonist.","date":"2013","source":"Journal of pharmaceutical and biomedical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/24042122","citation_count":41,"is_preprint":false},{"pmid":"23604599","id":"PMC_23604599","title":"GluN2A versus GluN2B: twins, but quite different.","date":"2013","source":"Neuroscience bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/23604599","citation_count":38,"is_preprint":false},{"pmid":"26041915","id":"PMC_26041915","title":"GluN2B-Containing NMDA Receptors Regulate AMPA Receptor Traffic through Anchoring of the Synaptic Proteasome.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26041915","citation_count":38,"is_preprint":false},{"pmid":"34354080","id":"PMC_34354080","title":"GluN2A and GluN2B NMDA receptors use distinct allosteric routes.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34354080","citation_count":37,"is_preprint":false},{"pmid":"27180168","id":"PMC_27180168","title":"Enhanced attention and impulsive action following NMDA receptor GluN2B-selective antagonist pretreatment.","date":"2016","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/27180168","citation_count":37,"is_preprint":false},{"pmid":"31548203","id":"PMC_31548203","title":"An autism-associated mutation in GluN2B prevents NMDA receptor trafficking and interferes with dendrite growth.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/31548203","citation_count":37,"is_preprint":false},{"pmid":"24292895","id":"PMC_24292895","title":"Potential involvement of GRIN2B encoding the NMDA receptor subunit NR2B in the spectrum of Alzheimer's disease.","date":"2013","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/24292895","citation_count":36,"is_preprint":false},{"pmid":"27976681","id":"PMC_27976681","title":"Amphetamine and Methamphetamine Increase NMDAR-GluN2B Synaptic Currents in Midbrain Dopamine Neurons.","date":"2016","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27976681","citation_count":36,"is_preprint":false},{"pmid":"37324591","id":"PMC_37324591","title":"GluN2B-containing NMDARs in the mammalian brain: pharmacology, physiology, and pathology.","date":"2023","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37324591","citation_count":35,"is_preprint":false},{"pmid":"30785307","id":"PMC_30785307","title":"GRIN2B promoter methylation deficits in early-onset schizophrenia and its association with cognitive function.","date":"2019","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/30785307","citation_count":35,"is_preprint":false},{"pmid":"21639937","id":"PMC_21639937","title":"Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma.","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21639937","citation_count":34,"is_preprint":false},{"pmid":"25454121","id":"PMC_25454121","title":"Overexpression of NMDAR2B in an inflammatory model of Alzheimer's disease: modulation by NOS inhibitors.","date":"2014","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/25454121","citation_count":33,"is_preprint":false},{"pmid":"27497478","id":"PMC_27497478","title":"Astrocytic GluN2A and GluN2B Oppose the Synaptotoxic Effects of Amyloid-β1-40 in Hippocampal Cells.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27497478","citation_count":33,"is_preprint":false},{"pmid":"26515544","id":"PMC_26515544","title":"Phosphorylation of NR2B NMDA subunits by protein kinase C in arcuate nucleus contributes to inflammatory pain in rats.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26515544","citation_count":33,"is_preprint":false},{"pmid":"21118530","id":"PMC_21118530","title":"NMDAR2B tyrosine phosphorylation regulates anxiety-like behavior and CRF expression in the amygdala.","date":"2010","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/21118530","citation_count":32,"is_preprint":false},{"pmid":"31291571","id":"PMC_31291571","title":"NMDAR-Activated PP1 Dephosphorylates GluN2B to Modulate NMDAR Synaptic Content.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31291571","citation_count":32,"is_preprint":false},{"pmid":"18983893","id":"PMC_18983893","title":"Association between NR2B subunit gene (GRIN2B) promoter polymorphisms and sporadic Alzheimer's disease in the North Chinese population.","date":"2008","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/18983893","citation_count":31,"is_preprint":false},{"pmid":"11080199","id":"PMC_11080199","title":"Transient expression of NMDA receptor subunit NR2B in the developing rat heart.","date":"2000","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11080199","citation_count":30,"is_preprint":false},{"pmid":"30089263","id":"PMC_30089263","title":"Noonan Syndrome-Associated SHP2 Dephosphorylates GluN2B to Regulate NMDA Receptor Function.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30089263","citation_count":30,"is_preprint":false},{"pmid":"26690829","id":"PMC_26690829","title":"Combined effect of genetic variants in the GluN2B coding gene (GRIN2B) on prefrontal function during working memory performance.","date":"2015","source":"Psychological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26690829","citation_count":29,"is_preprint":false},{"pmid":"35246269","id":"PMC_35246269","title":"Inhibition of CK2 mitigates Alzheimer's tau pathology by preventing NR2B synaptic mislocalization.","date":"2022","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/35246269","citation_count":27,"is_preprint":false},{"pmid":"19306263","id":"PMC_19306263","title":"Different expression of NR2B and PSD-95 in rat hippocampal subregions during postnatal development.","date":"2009","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/19306263","citation_count":27,"is_preprint":false},{"pmid":"25846226","id":"PMC_25846226","title":"Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure.","date":"2015","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/25846226","citation_count":27,"is_preprint":false},{"pmid":"38836461","id":"PMC_38836461","title":"Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology.","date":"2024","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/38836461","citation_count":26,"is_preprint":false},{"pmid":"31424425","id":"PMC_31424425","title":"TMEM25 modulates neuronal excitability and NMDA receptor subunit NR2B degradation.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31424425","citation_count":26,"is_preprint":false},{"pmid":"27616045","id":"PMC_27616045","title":"Mutation screening of GRIN2B in schizophrenia and autism spectrum disorder in a Japanese population.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27616045","citation_count":25,"is_preprint":false},{"pmid":"26211447","id":"PMC_26211447","title":"Schizophrenia: Evidence implicating hippocampal GluN2B protein and REST epigenetics in psychosis pathophysiology.","date":"2015","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26211447","citation_count":25,"is_preprint":false},{"pmid":"20067577","id":"PMC_20067577","title":"CASK phosphorylation by PKA regulates the protein-protein interactions of CASK and expression of the NMDAR2b gene.","date":"2010","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20067577","citation_count":25,"is_preprint":false},{"pmid":"35243557","id":"PMC_35243557","title":"Modulation of KIF17/NR2B crosstalk by tozasertib attenuates inflammatory pain in rats.","date":"2022","source":"Inflammopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35243557","citation_count":25,"is_preprint":false},{"pmid":"36138431","id":"PMC_36138431","title":"Disruption of grin2B, an ASD-associated gene, produces social deficits in zebrafish.","date":"2022","source":"Molecular autism","url":"https://pubmed.ncbi.nlm.nih.gov/36138431","citation_count":24,"is_preprint":false},{"pmid":"36694341","id":"PMC_36694341","title":"A decrease in NR2B expression mediated by DNA hypermethylation induces perioperative neurocognitive disorder in aged mice.","date":"2023","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36694341","citation_count":24,"is_preprint":false},{"pmid":"28456939","id":"PMC_28456939","title":"Genetic Mutation of GluN2B Protects Brain Cells Against Stroke Damages.","date":"2017","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28456939","citation_count":24,"is_preprint":false},{"pmid":"20957330","id":"PMC_20957330","title":"Psychosis and relapse in bipolar disorder are related to GRM3, DAOA, and GRIN2B genotype.","date":"2010","source":"African journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/20957330","citation_count":24,"is_preprint":false},{"pmid":"7959773","id":"PMC_7959773","title":"Mapping of the human NMDAR2B receptor subunit gene (GRIN2B) to chromosome 12p12.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7959773","citation_count":23,"is_preprint":false},{"pmid":"28258362","id":"PMC_28258362","title":"The effects of GRIN2B and DRD4 gene variants on local functional connectivity in attention-deficit/hyperactivity disorder.","date":"2018","source":"Brain imaging and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/28258362","citation_count":23,"is_preprint":false},{"pmid":"27394963","id":"PMC_27394963","title":"Association of GRIN2B gene polymorphism and Obsessive Compulsive disorder and symptom dimensions: A pilot study.","date":"2016","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/27394963","citation_count":23,"is_preprint":false},{"pmid":"33348808","id":"PMC_33348808","title":"Src/CK2/PTEN-Mediated GluN2B and CREB Dephosphorylations Regulate the Responsiveness to AMPA Receptor Antagonists in Chronic Epilepsy Rats.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33348808","citation_count":23,"is_preprint":false},{"pmid":"26051400","id":"PMC_26051400","title":"Different sites of alcohol action in the NMDA receptor GluN2A and GluN2B subunits.","date":"2015","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26051400","citation_count":23,"is_preprint":false},{"pmid":"27199241","id":"PMC_27199241","title":"The GRIN2B and GRIN2A Gene Variants Are Associated With Continuous Performance Test Variables in ADHD.","date":"2016","source":"Journal of attention disorders","url":"https://pubmed.ncbi.nlm.nih.gov/27199241","citation_count":22,"is_preprint":false},{"pmid":"29806151","id":"PMC_29806151","title":"Synthesis and Pharmacological Evaluation of Enantiomerically Pure GluN2B Selective NMDA Receptor Antagonists.","date":"2018","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/29806151","citation_count":22,"is_preprint":false},{"pmid":"25114227","id":"PMC_25114227","title":"Nicotinic and muscarinic agonists and acetylcholinesterase inhibitors stimulate a common pathway to enhance GluN2B-NMDAR responses.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25114227","citation_count":22,"is_preprint":false},{"pmid":"39395168","id":"PMC_39395168","title":"LTP expression mediated by autonomous activity of GluN2B-bound CaMKII.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39395168","citation_count":21,"is_preprint":false},{"pmid":"11891879","id":"PMC_11891879","title":"Differential NR2A and NR2B expression between trigeminal neurons during early postnatal development.","date":"2002","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11891879","citation_count":21,"is_preprint":false},{"pmid":"34685369","id":"PMC_34685369","title":"Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34685369","citation_count":21,"is_preprint":false},{"pmid":"33229564","id":"PMC_33229564","title":"Synaptotagmin-7 deficiency induces mania-like behavioral abnormalities through attenuating GluN2B activity.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33229564","citation_count":21,"is_preprint":false},{"pmid":"18952054","id":"PMC_18952054","title":"Activity-dependent NR2B expression is mediated by MeCP2-dependent epigenetic regulation.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18952054","citation_count":21,"is_preprint":false},{"pmid":"26020650","id":"PMC_26020650","title":"Association Study of N-Methyl-D-Aspartate Receptor Subunit 2B (GRIN2B) Polymorphisms and Schizophrenia Symptoms in the Han Chinese Population.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26020650","citation_count":21,"is_preprint":false},{"pmid":"25984336","id":"PMC_25984336","title":"Promising targets of cell death signaling of NR2B receptor subunit in stroke pathogenesis.","date":"2014","source":"Regenerative medicine research","url":"https://pubmed.ncbi.nlm.nih.gov/25984336","citation_count":20,"is_preprint":false},{"pmid":"19275891","id":"PMC_19275891","title":"CASK point mutation regulates protein-protein interactions and NR2b promoter activity.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19275891","citation_count":20,"is_preprint":false},{"pmid":"35697546","id":"PMC_35697546","title":"Fentanyl induces autism-like behaviours in mice by hypermethylation of the glutamate receptor gene Grin2b.","date":"2022","source":"British journal of anaesthesia","url":"https://pubmed.ncbi.nlm.nih.gov/35697546","citation_count":19,"is_preprint":false},{"pmid":"35893069","id":"PMC_35893069","title":"Molecular Insights into the Role of Pathogenic nsSNPs in GRIN2B Gene Provoking Neurodevelopmental Disorders.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35893069","citation_count":19,"is_preprint":false},{"pmid":"33420399","id":"PMC_33420399","title":"GluN2B and GluN2A-containing NMDAR are differentially involved in extinction memory destabilization and restabilization during reconsolidation.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33420399","citation_count":19,"is_preprint":false},{"pmid":"27605359","id":"PMC_27605359","title":"Further evidence for GRIN2B mutation as the cause of severe epileptic encephalopathy.","date":"2016","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/27605359","citation_count":19,"is_preprint":false},{"pmid":"17506933","id":"PMC_17506933","title":"Requirement of PSD-95 for dopamine D1 receptor modulating glutamate NR1a/NR2B receptor function.","date":"2007","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/17506933","citation_count":19,"is_preprint":false},{"pmid":"33038564","id":"PMC_33038564","title":"Childhood adversity increases methylation in the GRIN2B gene.","date":"2020","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/33038564","citation_count":18,"is_preprint":false},{"pmid":"31840160","id":"PMC_31840160","title":"Leptin Controls Glutamatergic Synaptogenesis and NMDA-Receptor Trafficking via Fyn Kinase Regulation of NR2B.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31840160","citation_count":18,"is_preprint":false},{"pmid":"29307084","id":"PMC_29307084","title":"GluN2B Subunit of the NMDA Receptor: The Keystone of the Effects of Alcohol During Neurodevelopment.","date":"2018","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/29307084","citation_count":18,"is_preprint":false},{"pmid":"34393725","id":"PMC_34393725","title":"An Autism-Associated de novo Mutation in GluN2B Destabilizes Growing Dendrites by Promoting Retraction and Pruning.","date":"2021","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34393725","citation_count":18,"is_preprint":false},{"pmid":"36527595","id":"PMC_36527595","title":"The Weakened Interaction Between HECTD4 and GluN2B in Ischemic Stroke Promotes Calcium Overload and Brain Injury Through a Mechanism Involving the Decrease of GluN2B and MALT1 Ubiquitination.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36527595","citation_count":18,"is_preprint":false},{"pmid":"38246915","id":"PMC_38246915","title":"Long-term plasticity of NMDA GluN2B (NR2B) receptor in anterior cingulate cortical synapses.","date":"2024","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/38246915","citation_count":17,"is_preprint":false},{"pmid":"36224322","id":"PMC_36224322","title":"Carnosic Acid Attenuates AβOs-Induced Apoptosis and Synaptic Impairment via Regulating NMDAR2B and Its Downstream Cascades in SH-SY5Y Cells.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36224322","citation_count":16,"is_preprint":false},{"pmid":"31672664","id":"PMC_31672664","title":"NR2B receptor- and calpain-mediated KCC2 cleavage resulted in cognitive deficiency exposure to isoflurane.","date":"2019","source":"Neurotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/31672664","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49218,"output_tokens":8815,"usd":0.139939,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18642,"output_tokens":4805,"usd":0.106667,"stage2_stop_reason":"end_turn"},"total_usd":0.246606,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"DAPK1 directly binds the NMDA receptor GluN2B C-terminal tail (amino acids 1292–1304) and, when constitutively active, phosphorylates GluN2B at Ser-1303, enhancing NR1/NR2B receptor channel conductance. Cerebral ischemia recruits DAPK1 into the GluN2B complex at extrasynaptic sites; genetic deletion of DAPK1 or a competing peptide (NR2B-CT) blocks injurious Ca2+ influx and is neuroprotective in mice.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, peptide competition, DAPK1 knockout mice, electrophysiology, stroke model\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay with phospho-site identification, reciprocal Co-IP, genetic KO, and peptide rescue in vivo; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"20141836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Dopamine D2 receptors (D2R) directly interact with the GluN2B subunit within the postsynaptic density of striatal neurons. Cocaine enhances this D2R–GluN2B complex formation, which disrupts CaMKII association with GluN2B, reduces GluN2B phosphorylation at Ser-1303, and inhibits NMDA receptor-mediated currents in striatal neurons.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, electrophysiology, behavioral cocaine model\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus in vitro pulldown plus electrophysiology; multiple orthogonal methods\",\n      \"pmids\": [\"17145509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Activated CaMKII couples GluN2B and casein kinase 2 (CK2) into a trimolecular complex, increasing CK2-mediated phosphorylation of GluN2B at S1480. A GluN2B mutant unable to bind CaMKII shows reduced S1480 phosphorylation and increased surface expression. Disrupting GluN2B/CaMKII binding reduces synapse number but increases synaptic GluN2B content.\",\n      \"method\": \"Co-immunoprecipitation, phospho-site mutagenesis, surface biotinylation, confocal imaging\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, mutagenesis, and surface expression assays with multiple orthogonal methods in one study\",\n      \"pmids\": [\"23478024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CaMKII binding to the GluN2B C-terminal tail is required for CaMKII synaptic accumulation, Thr286 autophosphorylation, GluR1 phosphorylation, hippocampal LTP, and spatial learning. Transgenic expression of a C-terminal GluN2B fragment that sequesters endogenous CaMKII disrupts these interactions and impairs plasticity and memory.\",\n      \"method\": \"Transgenic mouse (ligand-inducible NR2B fragment), immunoprecipitation, electrophysiology (LTP), Morris water maze\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic disruption with defined molecular readouts (phosphorylation, LTP, behavior), multiple orthogonal assays\",\n      \"pmids\": [\"18077696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Direct interaction between GluN2B and αCaMKII (but not βCaMKII) is required for GluN2B-dependent, long-lasting ERK1/2 phosphorylation following synaptic NMDAR activation. Disrupting this interaction prevents activity-induced increases in synaptic AMPA receptors and spine volume.\",\n      \"method\": \"Co-immunoprecipitation, pharmacological disruption of GluN2B/CaMKII binding, ERK phosphorylation assay, dendritic spine imaging\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, interaction-disrupting peptide, and multiple functional readouts in cultured cortical neurons\",\n      \"pmids\": [\"22855824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DAPK1 competes with CaMKII for binding to GluN2B. During LTD, calcineurin-dependent DAPK1 activation blocks CaMKII binding to GluN2B, preventing CaMKII synaptic accumulation. During LTP, Ca2+/CaM inhibits DAPK1/GluN2B binding, allowing CaMKII accumulation. A pharmacogenetic approach confirmed that suppression of CaMKII/GluN2B binding is a DAPK1-specific function required for LTD.\",\n      \"method\": \"Pharmacogenetic approach (GluN2B knock-in mice), electrophysiology (LTP/LTD), biochemical competition assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacogenetic mouse model combined with electrophysiology and biochemical assays; multiple orthogonal methods\",\n      \"pmids\": [\"28614711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GluN2B S1480 phosphorylation maintains NMDARs at extrasynaptic membranes within a complex containing protein phosphatase 1 (PP1). Global NMDAR activation leads to PP1 activation, which dephosphorylates GluN2B S1480 and promotes increased synaptic NMDAR content.\",\n      \"method\": \"Co-immunoprecipitation, phospho-site mutagenesis, surface biotinylation, electrophysiology\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, phospho-mutant analysis, and electrophysiology; multiple orthogonal methods in a single study\",\n      \"pmids\": [\"31291571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CaMKII/GluN2B interaction is required not only for LTP induction but also for the maintenance of basal synaptic strength, as shown by pharmacogenetic disruption using a CaMKII-binding-incompetent GluN2B knock-in mouse.\",\n      \"method\": \"Pharmacogenetic mouse (GluN2B CaMKII-binding mutant knock-in), electrophysiology, CaMKII inhibitor tatCN21\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacogenetic knock-in mouse with clean electrophysiological readouts; separates on-target from off-target effects\",\n      \"pmids\": [\"27246855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GluN2B binding to CaMKII directly generates Ca2+-independent autonomous CaMKII activity. This enzymatic activity is dispensable for LTP induction (within 5 min) but required for an intermediary LTP expression phase (within 15 min), providing an objective temporal definition for this LTP phase.\",\n      \"method\": \"Pharmacogenetic approach, electrophysiology, optogenetic CaMKII activation (CRY2 constructs), biochemical assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacogenetic plus optogenetic tools combined with electrophysiology; multiple orthogonal approaches in one study\",\n      \"pmids\": [\"39395168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GluN1/GluN2A/GluN2B triheteromeric NMDA receptors have distinct glutamate deactivation kinetics compared with GluN1/GluN2A and GluN1/GluN2B diheteromers, and show unique modulation by ifenprodil, CP-101,606, TCN-201, and extracellular Zn2+. The ifenprodil binding site of triheteromers differs kinetically from that of GluN1/GluN2B diheteromers.\",\n      \"method\": \"Engineered forced-expression system for exclusive triheteromeric surface expression, whole-cell electrophysiology, pharmacological profiling\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — recombinant receptor reconstitution with selective surface expression system plus rigorous electrophysiology and pharmacology\",\n      \"pmids\": [\"24607230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GluN2A and GluN2B receptors utilize distinct long-distance allosteric mechanisms involving different subunit–subunit interfaces and molecular rearrangements between their N-terminal domains (NTDs) and transmembrane channel pore.\",\n      \"method\": \"Functional electrophysiology combined with structural analysis (cryo-EM/X-ray), mutagenesis of subunit interfaces\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural interrogation combined with functional mutagenesis, multiple orthogonal methods\",\n      \"pmids\": [\"34354080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DAPK1 interaction with GluN2B at extrasynaptic sites is enhanced by chronic stress (CUS) in the rat prefrontal cortex, increasing GluN2B-mediated NMDA currents and extrasynaptic responses. Uncoupling DAPK1 from GluN2B (via DAPK1 knockdown, pharmacological inhibition, or competing peptide) produces rapid antidepressant-like effects and reverses CUS-induced synaptic deficits.\",\n      \"method\": \"AAV-shRNA knockdown, pharmacological inhibition, competing peptide, electrophysiology, behavioral tests\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple intervention strategies (genetic KD, pharmacology, peptide) with convergent electrophysiological and behavioral readouts\",\n      \"pmids\": [\"28439098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tyrosine phosphorylation of GluN2B at Tyr-1472 (the major phosphorylation site) negatively regulates anxiety-like behavior and CRF expression in the amygdala. Knock-in mice expressing GluN2B Y1472F (phosphorylation-deficient) show enhanced anxiety and elevated amygdalar CRF expression; CRF receptor antagonism attenuates this enhanced anxiety.\",\n      \"method\": \"Knock-in mice (Y1472F GluN2B), elevated plus-maze, CRF immunoassay, CRF receptor antagonist injection\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — phospho-site knock-in mouse with pharmacological rescue and multiple behavioral and molecular readouts\",\n      \"pmids\": [\"21118530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Src tyrosine kinase regulates GluN2B surface expression in amygdala neurons. A cell-permeable Src inhibitory peptide (Tat-Src 40-58) reduces GluN2B tyrosine phosphorylation and surface expression in amygdala neurons, blocks amygdalar LTP, and impairs amygdala-dependent fear conditioning and social recognition memory.\",\n      \"method\": \"Cell-permeable peptide, surface biotinylation, electrophysiology (LTP), fear conditioning behavioral assay\",\n      \"journal\": \"Learning & memory\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — peptide intervention with biochemical (phosphorylation, surface expression), electrophysiological, and behavioral readouts\",\n      \"pmids\": [\"20660101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GluN2B-containing NMDARs anchor the synaptic proteasome, regulating constitutive AMPA receptor endocytosis. In GluN2B-knockout neurons, synaptic proteasome subunit levels decrease, GluA1-AMPA receptor constitutive endocytosis is reduced, and synaptic AMPA receptor levels increase. Pharmacological enhancement of proteasome activity rescues these phenotypes.\",\n      \"method\": \"GluN2B-/- neuronal cultures, quantitative postsynaptic density proteomics, surface biotinylation, proteasome activator treatment\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO combined with quantitative proteomics and pharmacological rescue; multiple orthogonal readouts\",\n      \"pmids\": [\"26041915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Noonan syndrome-associated SHP2 dephosphorylates GluN2B at Y1252 (identified as an SHP2 substrate in vitro and in vivo). Phospho-Y1252 binds the actin-regulatory adaptor protein Nck2, and this interaction is required for proper NMDAR function. NS mice show selectively reduced GluN1:GluN2B diheteromer contribution to NMDAR currents.\",\n      \"method\": \"In vitro phosphatase assay, mass spectrometry, Co-immunoprecipitation, electrophysiology, NS knock-in mice\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro phosphatase assay with site identification, Co-IP, and electrophysiology in knock-in mice; multiple orthogonal methods\",\n      \"pmids\": [\"30089263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PKC activation in the arcuate nucleus enhances phosphorylation of GluN2B at Tyr-1472 without altering total GluN2B expression. Intra-ARC injection of the PKC inhibitor chelerythrine reverses CFA-induced upregulation of phospho-GluN2B(Tyr1472) and attenuates inflammatory hyperalgesia.\",\n      \"method\": \"In vivo microinjection, western blotting, in vivo extracellular electrophysiology, inflammatory pain model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological intervention with phospho-site western blotting and electrophysiology; single lab, two methods\",\n      \"pmids\": [\"26515544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"D-serine (but not glycine) alters the membrane dynamics and synaptic content of GluN2B-NMDARs (but not GluN2A-NMDARs) through a process requiring PDZ-binding scaffold partners. D-serine also rapidly induces a conformational change of the GluN1 subunit intracellular C-terminus domain, detected by FRET-FLIM.\",\n      \"method\": \"Single-molecule tracking, surface biotinylation, FRET-FLIM, electrophysiology, ex vivo and in vitro pharmacology\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — single-molecule imaging, FRET-FLIM, and electrophysiology provide multiple orthogonal lines of evidence in one study\",\n      \"pmids\": [\"28598327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"An ASD-associated truncating mutation in GluN2B (within the extracellular loop) abolishes NMDA-dependent Ca2+ influx. Mutant GluN2B co-assembles with GluN1 but is not trafficked to the cell surface or dendrites, and when expressed in developing cortical neurons causes shorter, fewer dendritic branches and dysmorphic filopodial-like structures even on a wild-type background.\",\n      \"method\": \"Calcium imaging, surface biotinylation, immunocytochemistry, dendritic morphology analysis in primary cortical neurons, HEK293 expression\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional Ca2+ assay, trafficking assay, and morphological analysis with multiple GluN2B constructs in primary neurons\",\n      \"pmids\": [\"31548203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TMEM25 interacts with GluN2B and co-localizes with it in late endosomes. TMEM25 induces lysosomal acidification and accelerates GluN2B degradation. Loss of TMEM25 increases GluN2B levels and neuronal excitability, while TMEM25 overexpression attenuates epileptic seizure phenotypes.\",\n      \"method\": \"Co-immunoprecipitation, confocal co-localization, lysosomal acidification assay, electrophysiology, overexpression/knockdown in mice, epilepsy model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP, co-localization, degradation assay, electrophysiology, and in vivo gain/loss-of-function; multiple orthogonal methods\",\n      \"pmids\": [\"31424425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Leptin receptor (LepRb) forms a complex with GluN2B and Fyn kinase. Leptin stimulates Fyn-dependent phosphorylation of GluN2B at Tyr-1472, increasing surface expression of NR2B-containing NMDARs. Blocking Y1472 phosphorylation (via dominant-negative Fyn or NR2B-Y1472F mutant) prevents leptin-stimulated glutamatergic synaptogenesis in hippocampal neurons.\",\n      \"method\": \"Co-immunoprecipitation, surface biotinylation, phospho-site mutagenesis, synapse morphometry, dominant-negative Fyn\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP, mutagenesis, surface trafficking assay, and synaptogenesis readout; multiple orthogonal methods in one study\",\n      \"pmids\": [\"31840160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Nicotinic and muscarinic ACh receptor agonists and acetylcholinesterase inhibitors converge on the m1 muscarinic receptor–Gαq–PKC–PYK2–Src signaling pathway to selectively enhance GluN2B-NMDAR responses in hippocampal CA1 pyramidal cells. In vivo cholinergic drug exposure occludes in vitro m1 and Src potentiation of NMDAR responses.\",\n      \"method\": \"In vivo drug administration, in vitro electrophysiology (whole-cell patch clamp), pharmacological dissection\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo–in vitro occlusion paradigm with multiple pharmacological probes defining a signaling pathway\",\n      \"pmids\": [\"25114227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PKA phosphorylation of CASK at Thr-724 in the guanylate kinase domain upregulates the CASK–Tbr-1 interaction. This complex activates the NMDAR2B promoter, and T724A CASK mutation abolishes cAMP-stimulated NMDAR2B expression in cortical neurons.\",\n      \"method\": \"In vitro PKA kinase assay, site-directed mutagenesis, Co-immunoprecipitation, NMDAR2B promoter-reporter assay, cortical neuron culture\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay with phospho-site identification, mutagenesis, Co-IP, and promoter reporter assay; multiple orthogonal methods\",\n      \"pmids\": [\"20067577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CASK Thr-724 point mutation in the GK domain selectively reduces CASK interactions with Tbr-1 and CINAP without affecting CASK dimerization, and diminishes NMDAR2B (NR2b) promoter activity, confirming that the CASK–Tbr-1–CINAP complex is required for NMDAR2B transcriptional regulation.\",\n      \"method\": \"Site-directed mutagenesis, Co-immunoprecipitation, promoter-reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus Co-IP plus promoter assay, single lab; confirms and extends PMID 20067577\",\n      \"pmids\": [\"19275891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Activity suppression (TTX treatment) increases GluN2B mRNA expression in cortical neurons, and this upregulation is occluded by DNMT inhibition. MeCP2 binds to the NR2B gene, and TTX reduces MeCP2 association with the NR2B locus, indicating that DNA methylation and MeCP2 binding mediate activity-dependent regulation of NR2B expression.\",\n      \"method\": \"TTX treatment of cortical neurons, RT-qPCR, chromatin immunoprecipitation (ChIP), DNMT inhibitor treatment, dark-rearing model\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP combined with pharmacological and activity-deprivation experiments; single lab, two orthogonal methods\",\n      \"pmids\": [\"18952054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GluN2B(F637) in the third membrane-associated domain regulates ethanol sensitivity and ion channel gating. Substitution mutations at F637 significantly alter ethanol IC50 values and glutamate EC50 values for peak and steady-state current, demonstrating this residue as a functional determinant of alcohol action on GluN2B-containing NMDARs.\",\n      \"method\": \"Site-directed mutagenesis, two-electrode voltage clamp in Xenopus oocytes, ethanol concentration–response analysis\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with functional electrophysiology; systematic structure–function analysis of ion channel residue\",\n      \"pmids\": [\"26051400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HECTD4 (an E3 ubiquitin ligase) interacts with GluN2B and ubiquitinates it. Ischemic stroke weakens this HECTD4–GluN2B interaction and reduces GluN2B ubiquitination. HECTD4 knockdown exacerbates NMDA/hypoxia-induced injury with increased GluN2B phosphorylation and Ca2+ overload, while MALT1 acts downstream of HECTD4 to regulate STEP61 and GluN2B phosphorylation.\",\n      \"method\": \"Nano-LC-MS/MS (interactome), Co-immunoprecipitation, siRNA knockdown, ubiquitination assay, Ca2+ imaging, ischemia rat model\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, and Ca2+ imaging; single lab with several orthogonal methods\",\n      \"pmids\": [\"36527595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Synaptotagmin-7 (Syt7) and GluN2B-NMDARs co-localize at the peripheral synaptic region in hippocampal neurons. Syt7 triggers multiple forms of glutamate release to activate juxtaposed GluN2B-NMDARs. Syt7 deficiency causes GluN2B-NMDAR hypoactivity and mania-like behavior in mice; this hypoactivity was rescued by Syt7 overexpression in patient iPSC-derived neurons.\",\n      \"method\": \"Super-resolution imaging, iPSC-derived neuron electrophysiology, Syt7 KO mice, lentiviral overexpression, behavioral assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — super-resolution co-localization, genetic KO, iPSC rescue experiment, and electrophysiology; multiple orthogonal methods\",\n      \"pmids\": [\"33229564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CK2 is aberrantly elevated in Alzheimer's disease (AD) brains, causing GluN2B to mislocalize from synaptic to extrasynaptic sites. CK2 inhibition corrects this NR2B synaptic distribution, reduces tau accumulation in vitro, and inhibiting excessive extrasynaptic GluN2B with memantine also mitigates tau pathology.\",\n      \"method\": \"Human AD brain immunohistochemistry, hippocampal neuron culture (AD-tau treatment), CK2 inhibitor treatment, synaptic fractionation, tau immunoassay\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human tissue combined with in vitro pharmacological rescue; single lab, two orthogonal approaches\",\n      \"pmids\": [\"35246269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Conditional deletion of the GluN2B C-terminal tail (amino acids 886–1269) in forebrain excitatory neurons disrupts DAPK1–GluN2B interaction and inhibits extrasynaptic but not synaptic NMDAR currents. This genetic manipulation protects neurons against ischemic stroke damage and improves behavioral outcomes in vivo.\",\n      \"method\": \"Conditional knockout mice, whole-cell electrophysiology, infarct volume measurement, behavioral tests\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with site-specific electrophysiological dissection of synaptic vs extrasynaptic currents, plus in vivo stroke model\",\n      \"pmids\": [\"28456939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GluN2B-containing NMDARs are required for extinction memory destabilization upon recall (shown by GluN2B antagonist RO25-6981 blocking reconsolidation-mediated memory recovery), whereas GluN2A-containing NMDARs are involved in restabilization (shown by GluN2A antagonist TCN201 impairment of retention).\",\n      \"method\": \"Intra-hippocampal drug microinfusion, inhibitory avoidance behavioral paradigm, pharmacological dissection\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological dissection with selective antagonists; single lab, behavioral readout\",\n      \"pmids\": [\"33420399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Amphetamine and methamphetamine increase GluN2B-NMDAR synaptic currents in midbrain dopamine neurons dependent on dopamine transporter-mediated drug entry. EAAT3 internalization caused by AMPH increases extracellular glutamate to activate GluN2B-containing NMDARs. GluN2B inhibitors reduce MA-stimulated locomotor activity without affecting basal activity.\",\n      \"method\": \"Whole-cell patch clamp in midbrain slices, selective GluN2B antagonists, MK-801 use-dependent block, dopamine transporter inhibition, behavioral locomotor assay\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — electrophysiology with multiple pharmacological probes plus use-dependent blocker to distinguish surface vs de novo receptor pools; behavioral confirmation\",\n      \"pmids\": [\"27976681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GluN2B and GluN2D play counteractive roles in the temporal development of somatosensory maps: GluN2B is expressed at asymmetric synapses of glutamatergic projection neurons and facilitates refinement of ascending pathway synapses, while GluN2D is expressed at asymmetric synapses of GABAergic interneurons and delays it indirectly.\",\n      \"method\": \"GluN2B+/- and GluN2D-/- mice, unilateral infraorbital nerve transection (critical period assay), immunoelectron microscopy for subunit localization\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic mouse models with anatomical subunit localization by immuno-EM and functional critical-period assays; multiple orthogonal methods\",\n      \"pmids\": [\"25164652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PSD-95 is required for dopamine D1 receptor modulation of GluN1a/GluN2B receptor function. D1R stimulation increases NMDA-mediated Ca2+ influx only when PSD-95 is co-expressed; this modulation is blocked by PKA and PKC inhibitors.\",\n      \"method\": \"HEK293 cell co-expression, Ca2+ imaging, pharmacological inhibition of PKA and PKC\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional Ca2+ assay with pharmacological dissection; single lab, recombinant system\",\n      \"pmids\": [\"17506933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human GRIN2B gene, encoding the NMDAR2B receptor subunit, was mapped to chromosome 12p12 by in situ hybridization and somatic cell hybrid analysis.\",\n      \"method\": \"Fluorescence in situ hybridization, somatic cell hybrid panel\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent mapping methods (FISH + somatic cell hybrids); foundational chromosomal localization\",\n      \"pmids\": [\"7959773\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GluN2B is the glutamate-binding regulatory subunit of diheteromeric (GluN1/GluN2B) and triheteromeric (GluN1/GluN2A/GluN2B) NMDA receptors that functions as a scaffold and signaling hub at postsynaptic densities and extrasynaptic membranes: its C-terminal tail directly binds CaMKII (promoting autonomous kinase activity and LTP), DAPK1 (which phosphorylates Ser-1303 to enhance channel conductance and mediate excitotoxic/LTD signaling), CK2 (which phosphorylates S1480 to control synaptic vs. extrasynaptic trafficking), Src/Fyn kinases (which phosphorylate Tyr-1472 to regulate surface expression and anxiety-related behavior), PP1 (which dephosphorylates S1480 to promote synaptic recruitment), and the E3 ligase HECTD4 (which ubiquitinates GluN2B to control its degradation), while the transmembrane domain residue F637 determines ethanol sensitivity; transcription of GRIN2B is regulated by the CASK–Tbr-1 complex (PKA-dependent), MeCP2-mediated DNA methylation, and epigenetic modifications including promoter hypermethylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GRIN2B encodes GluN2B, the glutamate-binding regulatory subunit of NMDA-type glutamate receptors that assemble as GluN1/GluN2B diheteromers and GluN1/GluN2A/GluN2B triheteromers, the latter exhibiting distinct deactivation kinetics and pharmacology (ifenprodil, Zn2+) from either diheteromer [#9], with GluN2A and GluN2B receptors using divergent long-distance allosteric coupling between N-terminal domains and the channel pore [#10]. The GluN2B C-terminal tail is a signaling and trafficking hub: it directly binds αCaMKII, an interaction that drives CaMKII synaptic accumulation, Thr286 autophosphorylation, GluR1 phosphorylation, ERK1/2 signaling, spine growth, hippocampal LTP, basal synaptic strength, and spatial learning, and additionally generates Ca2+-independent autonomous CaMKII activity required for an intermediary LTP phase [#3, #4, #7, #8]. DAPK1 competes with CaMKII for the same C-terminal region; calcineurin-dependent DAPK1 activation displaces CaMKII during LTD, while DAPK1 recruited to extrasynaptic GluN2B phosphorylates Ser-1303 to enhance channel conductance and drive excitotoxic Ca2+ influx in ischemia, chronic stress, and depression-related signaling [#0, #5, #11, #29]. Phosphorylation toggles control receptor localization: CaMKII couples GluN2B to CK2 to phosphorylate S1480 and retain receptors extrasynaptically, PP1 dephosphorylates S1480 to promote synaptic recruitment, and Src/Fyn-mediated Tyr-1472 phosphorylation (downstream of m1-Gαq-PKC-PYK2 and leptin receptor signaling) controls surface expression, anxiety behavior, fear memory, and synaptogenesis [#2, #6, #13, #20, #21], while SHP2 dephosphorylates Tyr-1252 to govern Nck2 binding and receptor function [#15]. GluN2B levels are further set by degradation via the E3 ligase HECTD4 and TMEM25-driven lysosomal turnover, and by anchoring of the synaptic proteasome that controls AMPA receptor endocytosis [#14, #19, #26]. GRIN2B transcription is regulated by the PKA-dependent CASK–Tbr-1–CINAP complex and by activity-dependent DNA methylation/MeCP2 binding [#22, #23, #24]. GluN2B-containing receptors mediate distinct cellular roles including somatosensory map refinement, extinction-memory destabilization, and responses to drugs of abuse, and a truncating ASD-associated mutation abolishes surface trafficking and Ca2+ influx and disrupts dendritic morphology [#18, #30, #31, #32].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing the chromosomal location of the human gene encoding the NMDAR2B subunit provided the genomic foundation for studying GRIN2B in human disease.\",\n      \"evidence\": \"FISH and somatic cell hybrid mapping to 12p12\",\n      \"pmids\": [\"7959773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional or regulatory information\", \"Does not address protein function or interactions\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defining the requirement of direct CaMKII binding to the GluN2B C-terminal tail answered how NMDAR activation is transduced into synaptic plasticity and memory.\",\n      \"evidence\": \"Transgenic CaMKII-sequestering GluN2B fragment with LTP and Morris water maze readouts; co-expression Ca2+ imaging with PSD-95\",\n      \"pmids\": [\"18077696\", \"17506933\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the temporal phases of CaMKII-dependent LTP\", \"Competition with other C-tail binders not yet addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identifying DAPK1 as a direct GluN2B partner that phosphorylates Ser-1303 at extrasynaptic sites revealed the molecular route from receptor to excitotoxic Ca2+ influx in stroke.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, DAPK1 KO mice, competing peptide in a stroke model\",\n      \"pmids\": [\"20141836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not yet establish DAPK1/CaMKII mutual exclusivity\", \"Synaptic vs extrasynaptic substrate selectivity mechanism unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linking Src/Fyn-dependent Tyr-1472 phosphorylation to GluN2B surface expression connected tyrosine signaling to anxiety and fear-related behaviors.\",\n      \"evidence\": \"Y1472F knock-in mice, Tat-Src inhibitory peptide, surface biotinylation, LTP and behavioral assays in amygdala\",\n      \"pmids\": [\"21118530\", \"20660101\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream kinase activation signals not fully mapped\", \"Phosphatase counteracting Y1472 not identified here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showing that activated CaMKII recruits CK2 to phosphorylate S1480 explained how a plasticity signal controls synaptic versus extrasynaptic receptor distribution.\",\n      \"evidence\": \"Co-IP, phospho-site mutagenesis, surface biotinylation, imaging\",\n      \"pmids\": [\"23478024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphatase reversing S1480 not yet identified\", \"In vivo relevance of the trimolecular complex untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Engineered triheteromeric receptors and subunit-localization studies resolved that GluN2B confers distinct kinetics, pharmacology, and developmental/circuit roles separable from GluN2A and GluN2D.\",\n      \"evidence\": \"Forced triheteromer surface expression with electrophysiology/pharmacology; GluN2B+/- and GluN2D-/- mice with immuno-EM and critical-period assays; cholinergic m1-PKC-PYK2-Src pathway dissection\",\n      \"pmids\": [\"24607230\", \"25164652\", \"25114227\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Native triheteromer stoichiometry in vivo not quantified\", \"Structural basis of altered ifenprodil site not yet resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapping a transmembrane determinant (F637) of ethanol and gating, plus a proteasome-anchoring role, expanded GluN2B function beyond ligand binding into channel pharmacology and protein turnover at synapses.\",\n      \"evidence\": \"F637 mutagenesis with two-electrode voltage clamp; GluN2B-/- neurons with PSD proteomics and proteasome activator rescue; PKC-Tyr1472 pain model\",\n      \"pmids\": [\"26051400\", \"26041915\", \"26515544\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"F637 ethanol mechanism is structure-function only, no in vivo behavior\", \"How GluN2B physically anchors the proteasome unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrating DAPK1/CaMKII mutual competition for GluN2B unified bidirectional plasticity, showing the same C-tail site switches between LTP and LTD depending on calcium signaling.\",\n      \"evidence\": \"Pharmacogenetic GluN2B knock-in mice, LTP/LTD electrophysiology, biochemical competition; D-serine single-molecule and FRET-FLIM trafficking study\",\n      \"pmids\": [\"28614711\", \"27246855\", \"28598327\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Timing of calcineurin-DAPK1 versus Ca2+/CaM signals not fully resolved\", \"Coactivator selectivity (D-serine vs glycine) mechanism partial\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying PP1-mediated S1480 dephosphorylation and TMEM25/lysosomal degradation defined the bidirectional control of GluN2B synaptic recruitment and abundance, while an ASD truncation linked trafficking failure to morphological disease phenotypes.\",\n      \"evidence\": \"Co-IP/phospho-mutant electrophysiology (PP1); Co-IP, lysosomal acidification and epilepsy model (TMEM25); Ca2+ imaging and dendritic morphology of ASD truncation\",\n      \"pmids\": [\"31291571\", \"31424425\", \"31548203\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How global NMDAR activity selectively activates PP1 at S1480 unknown\", \"Disease-mutation dominant-negative mechanism on WT receptors not fully defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connecting leptin receptor–Fyn–Tyr1472 signaling and Syt7-driven peripheral glutamate release placed GluN2B activity within metabolic and presynaptic release contexts relevant to synaptogenesis and mood.\",\n      \"evidence\": \"Co-IP, dominant-negative Fyn, synaptogenesis (leptin); super-resolution imaging, Syt7 KO mice and iPSC rescue (Syt7)\",\n      \"pmids\": [\"31840160\", \"33229564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial organization of the LepRb-GluN2B-Fyn complex unresolved\", \"Direct vs indirect Syt7-GluN2B coupling not biochemically defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Establishing HECTD4-mediated ubiquitination and CK2-driven extrasynaptic mislocalization tied GluN2B degradation and distribution to ischemic injury and Alzheimer's tau pathology.\",\n      \"evidence\": \"Interactome MS, Co-IP, ubiquitination and Ca2+ imaging in ischemia (HECTD4); human AD brain plus CK2 inhibitor and memantine rescue (CK2)\",\n      \"pmids\": [\"36527595\", \"35246269\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"HECTD4 ubiquitination sites on GluN2B not mapped\", \"Causality between CK2-driven mislocalization and tau accumulation is correlative in human tissue\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolving that GluN2B-induced autonomous CaMKII activity is dispensable for LTP induction but required for an intermediary expression phase gave a temporal mechanistic definition to CaMKII-dependent plasticity.\",\n      \"evidence\": \"Pharmacogenetic and optogenetic (CRY2) CaMKII activation with electrophysiology and biochemistry\",\n      \"pmids\": [\"39395168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of the autonomous activity in the 15-min phase not identified\", \"Relation to late-phase consolidation not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the competing C-terminal interactions (CaMKII, DAPK1, CK2, PP1, Src/Fyn, SHP2, HECTD4) are spatially and temporally coordinated into a single integrated decision about GluN2B localization, conductance, and degradation remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of competitive C-tail occupancy in vivo\", \"Stoichiometry of native synaptic vs extrasynaptic complexes unknown\", \"Quantitative cross-regulation among phospho-sites not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005216\", \"supporting_discovery_ids\": [9, 25]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [9, 10, 18]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 3, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 6, 13, 20]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"GO:0014069\", \"supporting_discovery_ids\": [1, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [3, 9, 32]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 13, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [22, 23, 24]}\n    ],\n    \"complexes\": [\n      \"GluN1/GluN2B NMDA receptor\",\n      \"GluN1/GluN2A/GluN2B triheteromeric NMDA receptor\",\n      \"CASK-Tbr-1-CINAP transcription complex\"\n    ],\n    \"partners\": [\n      \"CAMK2A\",\n      \"DAPK1\",\n      \"CSNK2A1\",\n      \"PPP1CA\",\n      \"FYN\",\n      \"PTPN11\",\n      \"HECTD4\",\n      \"TMEM25\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}